Macquarie’s price target of $18.60 for NEU includes a valuation of $15.30 for DayBue - $12.20 for DayBue in Rett syndrome in North America and $3.10 (using a 50% risk weighting) for DayBue in ROW markets.
NNZ-2591 is valued in total at just $3.30 - $2.00 for Phelan McDermid syndrome, using a 20% risk weighting, and $1.30 for Pitt Hopkins syndrome, using a 15% risk weighting.
No value is attributed to NNZ-2591 in Angelman syndrome or HIE.
It’s unfortunate that the report mistakenly identifies the conditions being targeted by Neuren as neurodegenerative rather than neurodevelopmental disorders.
NEU Price at posting:
$13.04 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)